COVID-19 gone bad: A new character in the spectrum of the hyperferritinemic syndrome?
Antiphospholipid Syndrome
Betacoronavirus
Blood Coagulation Disorders
COVID-19
Coronavirus Infections
/ physiopathology
Cytokine Release Syndrome
/ immunology
Ferritins
Humans
Inflammation
Macrophage Activation Syndrome
Pandemics
Pneumonia, Viral
/ physiopathology
SARS-CoV-2
Shock, Septic
Still's Disease, Adult-Onset
COVID-19
Cytokine storm
Ferritin
Inflammation
Journal
Autoimmunity reviews
ISSN: 1873-0183
Titre abrégé: Autoimmun Rev
Pays: Netherlands
ID NLM: 101128967
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
11
04
2020
accepted:
12
04
2020
pubmed:
11
5
2020
medline:
11
6
2020
entrez:
11
5
2020
Statut:
ppublish
Résumé
The severe form of COVID-19 share several clinical and laboratory features with four entities gathered under the term "hyperferritinemic syndromes" and including macrophage activation syndrome (MAS), adult-onset Still's disease (AOSD), catastrophic anti-phospholipid syndrome (CAPS) and septic shock. COVID-19 systemic inflammatory reaction and "hyperferritinemic syndromes" are all characterized by high serum ferritin and a life-threatening hyper-inflammation sustained by a cytokines storm which eventually leads to multi-organ failure. In this review, we analyze the possible epidemiological and molecular mechanisms responsible for hyper-inflammation in patients with severe COVID-19 and we underline the similarities between this condition and "hyperferritinemic syndromes" which would allow considering severe COVID-19 as a fifth member of this spectrum of inflammatory conditions.
Identifiants
pubmed: 32387470
pii: S1568-9972(20)30135-X
doi: 10.1016/j.autrev.2020.102573
pmc: PMC7199723
pii:
doi:
Substances chimiques
Ferritins
9007-73-2
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
102573Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2020 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The Authors have neither financial interests nor have received financial support or benefits from commercial sources for the work reported on in the manuscript, which could create a potential conflict of interest or the appearance of a conflict of interest with regard to the present work.
Références
Mod Rheumatol. 2018 Sep;28(5):849-857
pubmed: 29251027
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Immunol Res. 2014 Dec;60(2-3):177-83
pubmed: 25388964
J Heart Lung Transplant. 2020 May;39(5):408-409
pubmed: 32253113
Thromb Res. 2017 Jan;149:38-44
pubmed: 27886531
Ann Rheum Dis. 2020 May;79(5):666-667
pubmed: 32241791
Microsc Res Tech. 2012 Sep;75(9):1185-90
pubmed: 22488824
Med Mal Infect. 2020 Jun;50(4):382-383
pubmed: 32259560
Autoimmun Rev. 2007 Aug;6(7):457-63
pubmed: 17643933
J Clin Invest. 2020 May 1;130(5):2620-2629
pubmed: 32217835
Lancet Respir Med. 2020 Apr;8(4):420-422
pubmed: 32085846
Int J Antimicrob Agents. 2020 May;55(5):105954
pubmed: 32234467
Rheumatology (Oxford). 2019 Jan 1;58(1):5-17
pubmed: 29481673
Emerg Microbes Infect. 2020 Dec;9(1):558-570
pubmed: 32172672
Diabetes Res Clin Pract. 2020 Apr;162:108125
pubmed: 32224164
Ann Rheum Dis. 2017 Jan;76(1):166-172
pubmed: 27296321
Microbes Infect. 2020 Mar;22(2):72-73
pubmed: 32092539
Zhonghua Xue Ye Xue Za Zhi. 2020 Mar 28;41(0):E006
pubmed: 32220276
BMJ. 2020 Feb 19;368:m606
pubmed: 32075786
Virology. 2004 Nov 10;329(1):11-7
pubmed: 15476870
Innate Immun. 2017 Jan;23(1):3-10
pubmed: 27697850
Hepatology. 2009 Mar;49(3):887-900
pubmed: 19241483
Biochim Biophys Acta. 1996 Jul 31;1275(3):161-203
pubmed: 8695634
Nat Rev Rheumatol. 2016 May;12(5):259-68
pubmed: 27009539
BMC Med. 2013 Aug 22;11:185
pubmed: 23968282
J Heart Lung Transplant. 2020 May;39(5):496-497
pubmed: 32362394
Autoimmun Rev. 2014 Jul;13(7):708-22
pubmed: 24657513
J Autoimmun. 2008 Feb-Mar;30(1-2):84-9
pubmed: 18191543
Thromb Haemost. 2013 May;109(5):901-8
pubmed: 23572134
Chest. 1995 Nov;108(5):1303-14
pubmed: 7587434
Exp Hematol. 2006 Feb;34(2):159-66
pubmed: 16459184
Clin Exp Rheumatol. 2012 Jan-Feb;30(1):142; author reply 143
pubmed: 22272648
J Clin Pathol. 2020 May;73(5):239-242
pubmed: 32198191
Genes Immun. 2002 Nov;3(7):394-9
pubmed: 12424620
Integr Biol (Camb). 2014 May;6(5):486-510
pubmed: 24714688
Medicine (Baltimore). 2014 Oct;93(17):280-9
pubmed: 25398063
Sci Rep. 2017 Mar 06;7:43829
pubmed: 28262742
Nature. 2005 Jul 7;436(7047):112-6
pubmed: 16001071
JAMA Cardiol. 2020 Mar 27;:
pubmed: 32219357
Ann Rheum Dis. 2020 May;79(5):667-668
pubmed: 32241793
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Autoimmun Rev. 2020 Jun;19(6):102537
pubmed: 32251717
Blood. 2010 Sep 2;116(9):1574-84
pubmed: 20472835
Med Hypotheses. 1995 Feb;44(2):85-8
pubmed: 7596311
Int J Infect Dis. 2020 May;94:91-95
pubmed: 32173574
Infect Dis Rep. 2020 Mar 16;12(1):8543
pubmed: 32218915
Viral Immunol. 2012 Feb;25(1):29-36
pubmed: 22239234
JAMA. 2020 Mar 19;:
pubmed: 32191259
Chin Med J (Engl). 2020 Mar 20;:
pubmed: 32209890
Front Immunol. 2019 Feb 01;10:119
pubmed: 30774631
Arthritis Res Ther. 2019 Dec 11;21(1):275
pubmed: 31829244
Blood. 2004 Mar 15;103(6):2369-76
pubmed: 14615366
Autoimmun Rev. 2015 Nov;14(11):1066-71
pubmed: 26209907
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
N Engl J Med. 2020 Apr 23;382(17):e38
pubmed: 32268022
J Heart Lung Transplant. 2020 May;39(5):405-407
pubmed: 32362390
Autoimmun Rev. 2020 Jun;19(6):102538
pubmed: 32268212
Medicine (Baltimore). 2017 Jun;96(24):e6656
pubmed: 28614216
N Engl J Med. 2020 May 21;382(21):2012-2022
pubmed: 32227758
Clin Immunol. 2020 May;214:108393
pubmed: 32222466
PLoS One. 2018 May 22;13(5):e0195392
pubmed: 29787561
Ann Rheum Dis. 2018 Jun;77(6):840-847
pubmed: 29472362
J Biol Regul Homeost Agents. 2020 Mar 14;34(2):
pubmed: 32171193